148 related articles for article (PubMed ID: 22634372)
1. Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease.
Botta-Orfila T; Sànchez-Pla A; Fernández M; Carmona F; Ezquerra M; Tolosa E
Brain Res; 2012 Jul; 1466():152-7. PubMed ID: 22634372
[TBL] [Abstract][Full Text] [Related]
2. Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.
Botta-Orfila T; Tolosa E; Gelpi E; Sànchez-Pla A; Martí MJ; Valldeoriola F; Fernández M; Carmona F; Ezquerra M
Neurobiol Dis; 2012 Jan; 45(1):462-8. PubMed ID: 21946334
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
[TBL] [Abstract][Full Text] [Related]
4. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease.
Botta-Orfila T; Morató X; Compta Y; Lozano JJ; Falgàs N; Valldeoriola F; Pont-Sunyer C; Vilas D; Mengual L; Fernández M; Molinuevo JL; Antonell A; Martí MJ; Fernández-Santiago R; Ezquerra M
J Neurosci Res; 2014 Aug; 92(8):1071-7. PubMed ID: 24648008
[TBL] [Abstract][Full Text] [Related]
5. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
[TBL] [Abstract][Full Text] [Related]
6. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.
Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
Neurobiol Aging; 2015 Feb; 36(2):1105-9. PubMed ID: 25475535
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease.
Mutez E; Nkiliza A; Belarbi K; de Broucker A; Vanbesien-Mailliot C; Bleuse S; Duflot A; Comptdaer T; Semaille P; Blervaque R; Hot D; Leprêtre F; Figeac M; Destée A; Chartier-Harlin MC
Neurobiol Dis; 2014 Mar; 63():165-70. PubMed ID: 24269915
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
9. A trojan horse for Parkinson's disease.
Hu Y; Tong Y
Sci Signal; 2010 Apr; 3(116):pe13. PubMed ID: 20371768
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease.
Liu J; Zhou Y; Wang C; Wang T; Zheng Z; Chan P
Parkinsonism Relat Disord; 2012 Feb; 18(2):140-3. PubMed ID: 21924942
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease.
Lopez de Maturana R; Aguila JC; Sousa A; Vazquez N; Del Rio P; Aiastui A; Gorostidi A; Lopez de Munain A; Sanchez-Pernaute R
Neurobiol Aging; 2014 May; 35(5):1116-24. PubMed ID: 24360742
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation.
Isaias IU; Benti R; Goldwurm S; Zini M; Cilia R; Gerundini P; Di Fonzo A; Bonifati V; Pezzoli G; Antonini A
Mov Disord; 2006 Aug; 21(8):1144-7. PubMed ID: 16671078
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
15. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
[TBL] [Abstract][Full Text] [Related]
16. Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.
Bravo-San Pedro JM; Gómez-Sánchez R; Niso-Santano M; Pizarro-Estrella E; González-Polo RA; Fuentes JM
Biochem Soc Trans; 2012 Oct; 40(5):1129-33. PubMed ID: 22988877
[TBL] [Abstract][Full Text] [Related]
17. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
Daniëls V; Baekelandt V; Taymans JM
Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
[TBL] [Abstract][Full Text] [Related]
18. Mutations in LRRK2 as a cause of Parkinson's disease.
Giasson BI; Van Deerlin VM
Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
[TBL] [Abstract][Full Text] [Related]
19. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 Parkinson's disease: from animal models to cellular mechanisms.
Lin CH; Tsai PI; Wu RM; Chien CT
Rev Neurosci; 2011; 22(4):411-8. PubMed ID: 21679126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
